IL112677A - Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist - Google Patents

Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist

Info

Publication number
IL112677A
IL112677A IL11267795A IL11267795A IL112677A IL 112677 A IL112677 A IL 112677A IL 11267795 A IL11267795 A IL 11267795A IL 11267795 A IL11267795 A IL 11267795A IL 112677 A IL112677 A IL 112677A
Authority
IL
Israel
Prior art keywords
autoimmune
antagonist
pharmaceutical composition
effective amount
therapeutically effective
Prior art date
Application number
IL11267795A
Other languages
English (en)
Other versions
IL112677A0 (en
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22791827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL112677(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of IL112677A0 publication Critical patent/IL112677A0/xx
Publication of IL112677A publication Critical patent/IL112677A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11267795A 1994-03-14 1995-02-16 Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist IL112677A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21262994A 1994-03-14 1994-03-14

Publications (2)

Publication Number Publication Date
IL112677A0 IL112677A0 (en) 1995-05-26
IL112677A true IL112677A (en) 2000-01-31

Family

ID=22791827

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11267795A IL112677A (en) 1994-03-14 1995-02-16 Pharmaceutical composition for treating autoimmune conditions comprising a therapeutically effective amount of IL-12 or of an IL-12 antagonist

Country Status (14)

Country Link
US (1) US6338848B1 (de)
EP (4) EP2201959A3 (de)
JP (1) JP3798426B2 (de)
AT (1) ATE217533T1 (de)
AU (1) AU689236B2 (de)
CA (1) CA2185565C (de)
DE (1) DE69526728T3 (de)
DK (1) DK0750509T4 (de)
ES (1) ES2173953T5 (de)
IL (1) IL112677A (de)
PT (1) PT750509E (de)
TW (1) TW400233B (de)
WO (1) WO1995024918A1 (de)
ZA (1) ZA95960B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US20010055581A1 (en) * 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
PT936923E (pt) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
ATE305506T1 (de) * 1998-12-09 2005-10-15 Protein Design Labs Inc Verwendung von il-12 antikörpern zur behandlung von psoriasis
KR100659007B1 (ko) 1999-02-10 2007-02-28 미츠비시 웰파마 가부시키가이샤 아미드 화합물 및 그 의약으로서의 용도
AU2005200515B2 (en) * 1999-03-25 2006-07-13 AbbVie Deutschland GmbH & Co. KG Human antibodies that bind human IL-12 and methods for producing
EP2168984B1 (de) * 1999-03-25 2012-08-29 Abbott GmbH & Co. KG Humane Antikörper die humanes IL-12 binden und Herstellungsverfahren
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
JP4676049B2 (ja) * 1999-07-21 2011-04-27 生化学工業株式会社 Ｉｌ−１２産生抑制剤
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
EP1494710A4 (de) * 2002-03-26 2007-03-21 Centocor Inc Diabetes-relevante von immunoglobulin stammende proteine, zusammensetzungen, verfahren und verwendungszwecke
AU2004311630A1 (en) 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
US20060024722A1 (en) 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
EA016022B1 (ru) 2004-12-21 2012-01-30 Сентокор, Инк. Выделенное антитело млекопитающего против il-12 и способ изменения его активности
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500353A3 (de) 2005-08-19 2012-10-10 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
NZ598881A (en) 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
BRPI0908715A2 (pt) 2008-03-18 2016-05-03 Abbott Lab métodos para tratamento da psoríase
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
EP3002299A1 (de) 2008-06-03 2016-04-06 AbbVie Inc. Dual-variable- domain-immunglobuline und ihre verwendungen
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US20110243938A1 (en) * 2008-09-30 2011-10-06 Baylor Research Intitute Methods to Reduce B-Helper T Cells to Treat Autoimmune Diseases
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CA2812310A1 (en) * 2010-09-28 2012-04-19 Neumedicines, Inc. Uses of il-12 and the il-12 receptor positive cell in tissue repair and regeneration
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
DK2709651T3 (en) 2011-05-19 2018-01-08 Univ Rush Medical Center IL-12-P40 MONOMER, MONOCLONAL ANTIBODY AGAINST P40 HOMODIMER, AND A COMBINATION OF THE TWO FOR THE TREATMENT OF AUTO-IMMUNE DISEASE
US20140178335A1 (en) * 2011-07-27 2014-06-26 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
EP2970459A2 (de) 2013-03-15 2016-01-20 AbbVie Inc. Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EA201892190A1 (ru) 2016-03-29 2019-04-30 Янссен Байотек, Инк. Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11578124B2 (en) 2018-05-18 2023-02-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-IL12/IL23 antibody
PL3883606T3 (pl) 2018-09-24 2023-11-27 Janssen Biotech, Inc. Bezpieczny i skuteczny sposób leczenia wrzodziejącego zapalenia jelita grubego przeciwciałami anty-il12/il23
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
DK0790255T3 (da) 1989-12-22 2007-11-26 Hoffmann La Roche Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
EP0638644A1 (de) * 1993-07-19 1995-02-15 F. Hoffmann-La Roche Ag Interleukin-12 Rezeptoren und Antikörper
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
HU230048B1 (hu) * 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041232A2 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
US8700033B2 (en) 2008-08-22 2014-04-15 International Business Machines Corporation Dynamic access to radio networks
CN102377479B (zh) 2010-08-11 2015-01-21 华为技术有限公司 数据同步方法及系统、光网络单元

Also Published As

Publication number Publication date
AU689236B2 (en) 1998-03-26
EP1179348A2 (de) 2002-02-13
EP2311484A1 (de) 2011-04-20
TW400233B (en) 2000-08-01
WO1995024918A1 (en) 1995-09-21
PT750509E (pt) 2002-08-30
EP1179348A3 (de) 2003-12-03
AU1974995A (en) 1995-10-03
DE69526728T3 (de) 2007-01-04
DK0750509T3 (da) 2002-07-08
CA2185565C (en) 2009-02-03
DE69526728D1 (de) 2002-06-20
EP0750509B1 (de) 2002-05-15
DE69526728T2 (de) 2002-11-21
ES2173953T5 (es) 2007-03-01
DK0750509T4 (da) 2006-10-16
JPH09510444A (ja) 1997-10-21
EP0750509A1 (de) 1997-01-02
EP0750509B2 (de) 2006-06-14
IL112677A0 (en) 1995-05-26
CA2185565A1 (en) 1995-09-21
JP3798426B2 (ja) 2006-07-19
EP2201959A3 (de) 2011-03-16
US6338848B1 (en) 2002-01-15
ATE217533T1 (de) 2002-06-15
ZA95960B (en) 1995-10-10
ES2173953T3 (es) 2002-11-01
EP2201959A2 (de) 2010-06-30

Similar Documents

Publication Publication Date Title
EP1179348A3 (de) Verwendung von il-12 und il-12 antagonisten für behandlung von autoimmunkrankheiten
ATE411029T1 (de) Estrogene als antimitotika
DK0754048T3 (da) Behandling af partielt væksthormon-insentivitetssyndrom
ES485450A1 (es) Procedimiento de preparacion de agentes de tratamiento de fibras queratinicas
AU582920B2 (en) Continuous release pharmaceutical compositions
GB2063671B (en) Composition for the treatment of keratin fibred based on amphoteric polymers and cationic polymers
NO934768L (no) Sammensetning av L-DOPA-estere
WO1994007535A3 (en) Labelled interleukin-8 and medical uses thereof
KR950700755A (ko) 장기간 자기면역 상태의 치료를 위한 미코박테리아 바케(Mycobacterium vaccae for treatment of long term autoimmune conditions)
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
DK399288D0 (da) Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion
WO1995013805B1 (en) Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
TW287948B (de)
AU7484791A (en) Method of treating diseases associated with elevated levels of interleukin 1
WO2000067764A3 (en) Improved method for treating mammals with modified mammalian blood
BE893492A (fr) Procede de preparation d'esters d'acides apovincaminiques, esters ainsi obtenus et compositions pharmaceutiques prepares avec ces esters
ITMI911215A0 (it) Esteri arilalchilici dell'acido 4,5 diidrossi-9,10-diosso-2-antracencarbossilico ad azione terapeutica
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
EP0318889A3 (de) Verfahren zur Behandlung von Dyslipämie beim Menschen
FR2714385B1 (fr) Copolymère d'acide phosphonique-carboxylique et procédé de préparation de ce copolymère.
Shimoda et al. Follow-up Study of Splinting for Pollux Rigidus
FR2703680B1 (fr) Structure cristalline d'halogénure de 2-amino-5-nitropyridinium, procédé de préparation desdites structures cristallines, et dispositif à effet électrooptique comportant de telles structures.
Greenberg et al. " Emotional disclosure about traumas and its relation to health: Effects of previous disclosure and trauma severity": Correction to Greenberg and Stone.
Mason The effect of externally administered propionate on lactate efflux from frog sartorius muscles.
FR2696180B1 (fr) Nouvelles céphalosporines comportant en position 7, un radical benzyloxyimino substitué, leur procédé de préparation et leur application comme médicaments.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired